Generic Genosyl Availability
Last updated on Sep 11, 2024.
Genosyl is a brand name of nitric oxide, approved by the FDA in the following formulation(s):
GENOSYL (nitric oxide - gas;inhalation)
-
Manufacturer: VERO BIOTECH INC
Approval date: December 20, 2019
Strength(s): 800PPM [RLD]
Has a generic version of Genosyl been approved?
No. There is currently no therapeutically equivalent version of Genosyl available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Genosyl. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Conversion of nitrogen dioxide (NO) to nitric oxide (NO)
Patent 10,124,142
Issued: November 13, 2018
Inventor(s): Rounbehler David P. & Fine David H.
Assignee(s): VERO BIOTECH LLCInhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
-
Nitrogen dioxide storage cassette
Patent 10,213,572
Issued: February 26, 2019
Inventor(s): Gellman Barry N. & Tajudeen Eddie & Gamero Lucas & Hopkins Joshua & Bromberg Edward E. A. & Denton Ryan & Johnson Bryan J. & Fine David
Assignee(s): VERO BIOTECH LLCA nitric oxide delivery system can include a cassette which is a single use disposable component used to store liquid NO, activate upon operator demand, convert NOto NOvia a heating element(s) controlled by a console to deliver NOat a controlled flow rate, direct concentrated NOto a contained pair of conversion cartridges and exhaust NO gas to the console for delivery to the patient.
Patent expiration dates:
- February 12, 2036✓
- February 12, 2036
-
Nitrogen dioxide storage device
Patent 10,737,051
Issued: August 11, 2020
Inventor(s): Gellman Barry N. & Tajudeen Eddie & Gamero Lucas & Hopkins Joshua & Bromberg Edward E. A. & Denton Ryan & Johnson Bryan J. & Fine DavidA nitric oxide delivery system can include a cassette which is a single use disposable component used to store liquid NO, activate upon operator demand, convert NOto NOvia a heating element(s) controlled by a console to deliver NOat a controlled flow rate, direct concentrated NOto a contained pair of conversion cartridges and exhaust NO gas to the console for delivery to the patient.
Patent expiration dates:
- October 20, 2035✓
- October 20, 2035
-
Conversion of nitrogen dioxide (NO) to nitric oxide (NO)
Patent 10,814,092
Issued: October 27, 2020
Inventor(s): Rounbehler David P. & Fine David H.
Assignee(s): VERO Biotech LLCInhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.
Patent expiration dates:
- October 17, 2025✓
- October 17, 2025
-
Systems and devices for generating nitric oxide
Patent 10,926,054
Issued: February 23, 2021
Inventor(s): Fine David H. & Johnson Bryan & Vasquez Gregory
Assignee(s): Vero Biotech LLCVarious systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.
Patent expiration dates:
- August 13, 2029✓
- August 13, 2029
-
Nitric oxide therapies
Patent 11,103,669
Issued: August 31, 2021
Inventor(s): Fine David H.
Assignee(s): Vero Biotech LLCA method for delivering nitric oxide therapy to a subject can include administering a composition including a nitric-oxide releasing agent and silica to the subject and releasing a therapeutic amount of nitric oxide from the composition.
Patent expiration dates:
- June 21, 2030✓
- June 21, 2030
-
Conversion of nitrogen dioxide (NO) to nitric oxide (NO)
Patent 11,291,793
Issued: April 5, 2022
Inventor(s): Rounbehler David P. & Fine David H.
Assignee(s): VERO Biotech Inc.Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
-
Patent 11,383,059
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
-
Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent 11,511,252
Issued: November 29, 2022
Inventor(s): Fine David H. & Rounbehler David P. & Vasquez Gregory & Johnson Bryan
Assignee(s): VERO Biotech Inc.A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.
Patent expiration dates:
- September 21, 2029✓
- September 21, 2029
-
Patent 11,554,241
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
-
Patent 11,672,938
Patent expiration dates:
- July 22, 2040✓
- July 22, 2040
-
Patent 7,560,076
Patent expiration dates:
- April 21, 2027✓
- April 21, 2027
-
Patent 7,618,594
Patent expiration dates:
- October 17, 2026✓
- October 17, 2026
-
Patent 7,947,227
Patent expiration dates:
- October 17, 2026✓
- October 17, 2026
-
Patent 8,057,742
Patent expiration dates:
- January 18, 2026✓
- January 18, 2026
-
Conversion of nitrogen dioxide (NO) to nitric oxide (NO)
Patent 8,226,916
Issued: July 24, 2012
Inventor(s): Rounbehler David R. & Fine David H.
Assignee(s): Geno LLCInhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
-
Systems and devices for generating nitric oxide
Patent 8,607,785
Issued: December 17, 2013
Inventor(s): Fine David H. & Johnson Bryan & Vasquez Gregory
Assignee(s): Geno LLCVarious systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.
Patent expiration dates:
- July 14, 2030✓
- July 14, 2030
-
Conversion of nitrogen dioxide (NO) to nitric oxide (NO)
Patent 8,609,028
Issued: December 17, 2013
Inventor(s): Rounbehler David R. & Fine David H.
Assignee(s): Geno LLCInhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
-
Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent 8,821,801
Issued: September 2, 2014
Inventor(s): Rounbehler David R. & Fine David H.
Assignee(s): Geno LLCA nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
-
Systems and devices for generating nitric oxide
Patent 8,944,049
Issued: February 3, 2015
Inventor(s): Fine David H. & Johnson Bryan & Vasquez Gregory
Assignee(s): GENO LLCVarious systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.
Patent expiration dates:
- August 13, 2029✓
- August 13, 2029
-
Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent 9,522,249
Issued: December 20, 2016
Inventor(s): Rounbehler David P. & Fine David H.
Assignee(s): GENO LLCInhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
-
Systems and devices for generating nitric oxide
Patent 9,604,028
Issued: March 28, 2017
Inventor(s): Fine David H. & Johnson Bryan & Vasquez Gregory
Assignee(s): GENO LLCVarious systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.
Patent expiration dates:
- August 13, 2029✓
- August 13, 2029
-
Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent 9,701,538
Issued: July 11, 2017
Inventor(s): Fine David H. & Vasquez Gregory & Rounbehler David P.
Assignee(s): GENO LLCVarious systems, devices, NOabsorbents, NOscavengers and NOrecuperator for generating nitric oxide are disclosed herein. According to one embodiment, an apparatus for converting nitrogen dioxide to nitric oxide can include a receptacle including an inlet, an outlet, a surface-active material coated with an aqueous solution of ascorbic acid and an absorbent wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the surface-active material and the absorbent such that nitrogen dioxide in the gas flow is converted to nitric oxide.
Patent expiration dates:
- January 28, 2029✓
- January 28, 2029
-
Conversion of nitrogen dioxide (NO) to nitric oxide (NO)
Patent 9,956,373
Issued: May 1, 2018
Inventor(s): Rounbehler David P. & Fine David H.
Assignee(s): GENO LLCA nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.
Patent expiration dates:
- August 18, 2025✓
- August 18, 2025
More about Genosyl (nitric oxide)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous respiratory agents
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.